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tients. Control of androgens was highly variable with a normal serum androstenedione found in
only 36% of patients, whereas 38% had suppressed levels suggesting glucocorticoid overtreat-
ment. In comparison with Health Survey for England participants, CAH patients were significantly
shorter and had a higher body mass index, and women with classic CAH had increased diastolic
blood pressure. Metabolic abnormalities were common, including obesity (41%), hypercholester-
olemia (46%), insulin resistance (29%), osteopenia (40%), andosteoporosis (7%). Subjectivehealth
status was significantly impaired and fertility compromised.
Conclusions: Currently, a minority of adult United Kingdom CAH patients appear to be under
endocrine specialist care. In the patients studied, glucocorticoid replacement was generally non-
physiological, and androgen levels were poorly controlled. This was associated with an adverse
metabolic profile and impaired fertility and quality of life. Improvements in the clinical manage-
ment of adults with CAH are required. (J Clin Endocrinol Metab 95: 5110–5121, 2010)
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.
Copyright © 2010 by The Endocrine Society
doi: 10.1210/jc.2010-0917 Received April 21, 2010. Accepted July 23, 2010.
First Published Online August 18, 2010
Abbreviations: BMI, Bodymass index;CAH, congenital adrenal hyperplasia;HADS,Hospital
Anxiety and Depression Scale; HSE, Health Surveys for England; IIEF-5, five-item version of
the International Index of Erectile Function; 17OHP, 17-hydroxyprogesterone; SF-36, 36-
item short-form health survey; TART, testicular adrenal rest tumor.
O R I G I N A L A R T I C L E
E n d o c r i n e R e s e a r c h
5110 jcem.endojournals.org J Clin Endocrinol Metab, November 2010, 95(11):5110–5121
Congenital adrenal hyperplasia (CAH) is the commonestgenetic endocrine disorder (1). Mutations in the 21-
hydroxylase gene, a key enzyme in cortisol and aldosterone
synthesis, account for 95% of cases (2, 3). 21-Hydroxylase
deficiency has an incidence of one in 12,000 live births for
severemutationscausingclassicCAH,whichmanifests inthe
neonatal period or during childhood, one in 2500 formilder
mutations causing nonclassic CAH manifesting during
adolescence or early adulthood (2, 3). In CAH, failure
in cortisol synthesis results in reduced cortisol feedback
and consequently increased pituitary ACTH release,
which promotes oversecretion of 17-hydroxyprogester-
one (17OHP), progesterone, and adrenal androgens. This
results in androgen excess that clinically manifests with dis-
orderedsexdevelopment ingirls,precociouspseudopuberty,
and short stature and in adulthoodwith hirsutism in females
and fertility problems in both sexes.
Glucocorticoid replacement inCAHaims both to replace
cortisol and prevent ACTH-driven androgen excess. This is
challenging, because therapy aiming to normalize ACTH
and reduce androgen levels frequently results in excess glu-
cocorticoid exposure with associated complications includ-
ing short stature, obesity, hypertension, and an adversemet-
abolic profile (4, 5). Striking the balance between too much
and too little glucocorticoid treatment is especially difficult
becausecurrentlyavailableglucocorticoid formulationscan-
not replicate the physiological circadian rhythm of cortisol
secretion (6–8).
CAH is a life-long chronic disorder. In childhood, treat-
ment focuses on issues of gender assignment, genital sur-
gery, and optimization of growth and pubertal develop-
ment (2, 3). Priorities change with increasing age (4, 5, 9),
typically focusing on fertility in early adult life and pre-
ventionofmetabolic syndromeandosteoporosis inmiddle
and older age, respectively.
ChildrenwithCAHaremanagedusing establishedguide-
lines (10) recommending amultidisciplinary team approach
including a pediatric endocrinologist, geneticist, urologist,
gynecologist, psychologist, and specialist nurses. No such
consensus exists for the management of adults with CAH.
There is a paucity of data from cohorts of meaningful size,
with previous reports focusedon relatively small numbers of
patients under the care of single treatment centers (11–14).
Therefore we performed a large, multicenter cross-sectional
study assessing the subjective and objective health status of
adults with CAH in the United Kingdom.
Patients and Methods
Patient recruitment
Leading up to this study, the Society for Endocrinology sent a
questionnaire to all United Kingdom centers providing specialist
endocrine care (n  30). Replies were received from 27 centers
(90%), indicating active involvement in the care of CAH adults,
with approximately one third of consultants looking after either
fewer than 10, 10–20, or more than 20 adult CAH patients. All
centers were asked whether they were interested to participate in a
nationwide audit. Seventeen centers, including all that reported
more than 20 adult CAH patients under their care, agreed to par-
ticipate. The United Kingdom Congenital Adrenal Hyperplasia
Adult Study Executive (CaHASE) was formed and the study pro-
tocol approved by West Midlands MREC (MREC/03/7/086) and
registered with www.ClinicalTrials.gov (NCT00749593). All cen-
ters contacted adult patients (18 yr or older) with a confirmed di-
agnosis of CAH currently under their care; recruitment startedAu-
gust 2004 and ended July 2007. All participants gave written
informed consent.
Procedures
Participants attended the research unit of their respective center
after an overnight fast and having taken their regular medication,
followed by medical history, physical examination, and fasting
blood sampling with the patient seated after being erect. After
breakfast, patients completed psychometric questionnaires.
Physical examination included blood pressure (three seated
and one standing, separated by 5 min), height, weight, waist
circumference, presence and degree of stretch marks, and in fe-
male patients hirsutism and in males testicular volume (or-
chidometer) and palpation for masses.
Biochemical assessment included renal and liver function,
fasting plasma glucose, serum insulin, cholesterol (total, low-
density lipoprotein, and high-density lipoprotein), triglycerides,
plasma renin activity, and steroid hormones including 17OHP,
androstenedione, testosterone, and SHBG. The median (inter-
quartile range) for the time from intake of last glucocorticoid
dose until blood sampling was 3.75 (2.25–12.5) hours. Mea-
surements were performed at local laboratories and results re-
corded as either below, within, or above the local reference
range, apart from 17OHP, androstenedione, and plasma renin
where absolute values were compared with previously recom-
mended target ranges for patients with CAH and adrenal insuf-
ficiency (1, 5).All laboratories participate in theUnitedKingdom
National External Quality Assessment Service scheme for qual-
ity control of steroid immunoassays. Serum insulin was mea-
sured centrally using an ultrasensitive ELISA (DRG Instruments,
Marburg, Germany) and used for calculation of homeostasis
model assessmentof insulin resistance (15). Bonemineral density
(BMD) assessed by dual x-ray absorptiometry and testicular ul-
trasound scans performed within the last 5 yr were recorded.
Psychometric evaluation was carried out employing self-ad-
ministered questionnaires, including three validated question-
naires for the assessment of subjective health status [36-item
short-formhealth survey (SF-36) (16, 17)],mood [HospitalAnx-
iety andDepression Scale (HADS) (18)], and sexuality [five-item
version of the International Index of Erectile Function (IIEF-5) in
men (19) and the nine-item short form of the McCoy Female
Sexuality Questionnaire (MFSQ-9) in women (20)] and a dis-
ease-specific questionnaire (CAHWellbeing) designed as a four-
level Likert scale for this study (see Supplemental Appendix,
published on The Endocrine Society’s Journals Online web site
at http://jcem.endojournals.org).
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Statistical analysis
Data from anonymized clinical case record forms were en-
tered into a central database. Differences between subgroups
were tested using t tests for comparison of means of continuous
variables and 2 tests for categorical variables. Sex-specific com-
parisons of anthropometric and blood pressure data with the
general populationweremade using age-weighted data for CAH
participants and data from Health Surveys for England (HSE)
(2006 data for anthropometric comparison and 2003 data for
blood pressure comparisons because blood pressure data were
not available in the 2006 survey) (21, 22).
Reference data for SF-36 scores were obtained from John
Brazier (University of Sheffield, Sheffield, UK) comprising a rep-
resentative random sample of 14,430 subjects from the United
Kingdom population aged between 18 and 79 yr. HADS refer-
ence data (n  2081) were obtained from Andreas Hinz (Uni-
versity of Leipzig, Leipzig,Germany). For everyCAHpatient, 20
(SF-36) or five (HADS) sex- and age-matched controls were
randomly selected fromthe respective reference samples for com-
parison. Adjustment for age and sex was performed by trans-
formation of score values from patients and controls into age-
adjusted (decade) and sex-adjusted z-scores, with subsequent
comparison byMann-WhitneyU test. Analyses were performed
using Stata version 10 (College Station, TX) and SPSS version
13.0 (SPSS Inc., Chicago, IL). Statistical significance was as-
sumed when P  0.05.
Results
Patient cohort
A total of 373 adult CAH patients
were contacted, and 203 (54%) agreed
to participate. Based on United King-
dom population data (Office of Na-
tional Statistics) and a presumed classic
CAHprevalence of one in 12,000 (2, 3),
we would expect 3591 adults with clas-
sic CAH between ages of 18 and 74 yr
(1778 men and 1813 women). Thus,
the number of patients recruited repre-
sents only a small fraction of the ex-
pected number, with overall capture
rates as low as 5 and 3% for female and
male classic CAH patients, respectively
(Fig. 1). The incidence of nonclassic
CAH is much greater but variable be-
tweenpopulations and is unknown in the
United Kingdom; however, recruitment
for these patients was very much lower
than for patients with classic CAH.
In the cohort of 203 patients, 199
had 21-hydroxylase deficiency, three
11-hydroxylase deficiency, and one
3-hydroxysteroid dehydrogenase de-
ficiency.Topreserve homogeneity, sub-
sequent analysis focused on the 199 pa-
tients with 21-hydroxylase deficiency
[134 women with a median age of 34
(range 18–69) years and 65 men with a median age of 32
(18–56) years]. Subgroup-specific age distribution in the 21-
hydroxylase deficiency patientswas as follows:womenwith
classicCAH (n103), 33 (18–66) years;womenwith non-
classic CAH (n  34), 43 (22–69) years; men with classic
CAH (n 62), 32 (18–56) years; and men with nonclassic
(n  3), 19, 36, and 36 yr. Ethnic origin was 91% white
European, 3% Asian (Pakistani), 1.5% African-Caribbean,
and 4.5% other.
Diagnosis had been established in the majority during
the neonatal period, either due to ambiguous genitalia
(34%) or salt-losing crisis (39%). Other primary mani-
festations included failure to thrive (5%),precociouspseu-
dopuberty (9.5%), tall stature (3.5%), hirsutism (9.5%),
oligo-/amenorrhea (7.5%), and family screening (8%).
Glucocorticoid therapy (Table 1)
Among women with classic CAH, 48% received pred-
nisolone, 17% dexamethasone, and 20% hydrocortisone.
Females with nonclassic CAH showed a similar distribution
(55%prednisolone, 16%dexamethasone, and 16%hydro-
cortisone), whereas men were more frequently treated with
FIG. 1. Expected and recruited number of CAH patients in the United Kingdom. Age
distribution of recruited male (A) and female (B) CAH patients from 17 endocrine specialist
centers across the United Kingdom (C) in comparison with the expected number of classic
CAH patients based on United Kingdom population data (Office of National Statistics) and an
assumed incidence of one in 12,000 newborns. A and B show absolute numbers (white bars,
normal population; black bars, CAH patients); D shows percentage of the expected patient
number per age group (gray bars, males; black bars, females).
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hydrocortisone (37%). Hydrocortisone and prednisolone
were mostly administered twice daily (61 and 75%, respec-
tively),whereasdexamethasonewasadministeredoncedaily
in 78%. Combined treatment with two or three different
glucocorticoid preparations was most frequent in females
with classic CAH (14 vs. 6% in both men with classic and
women with nonclassic CAH). Females with classic CAH
were also most likely to receive reverse circadian glucocor-
ticoid administration (50 vs.34 and35% inmale classic and
female nonclassic CAH patients, respectively). Glucocorti-
coid doses varied widely, with some patients receiving high
doses thatwe consider likely to cause signs and symptomsof
glucocorticoid excess.
Eighty-two percent of men with classic CAH, 72% of
women with classic CAH, and 10% of female nonclassic
CAH patients received mineralocorticoid replacement
with fludrocortisone. Of those treated with fludrocorti-
sone, 65%had plasma renin levels outside the therapeutic
target range, i.e. the upper half of the normal reference
range (1); 12%had lowor suppressed renin, and 53%had
too high renin levels. About one third of patients without
mineralocorticoid replacement had raised renin levels.
Serum steroid hormones (Fig. 2)
Testosterone levels within the reference range were
found inonly55%of classic and62%of femalenonclassic
CAH patients, and only 36% of patients in both groups
had normal levels of androstenedione. Suppressed andro-
stenedione (3 nmol/liter) and testosterone levels (0.5
nmol/liter)were found in 38 and 16%of the female classic
and in 44 and 10% of female nonclassic CAH patients,
respectively. By contrast, increased androstenedione (11
nmol/liter) and testosterone (2.5 nmol/liter) levels were
TABLE 1. Glucocorticoid treatment in the 21-hydroxylase deficiency patients in the United Kingdom CaHASE cohort
(n  199)
Glucocorticoid treatment
Male classic
CAH (n  62)
Female classic
CAH (n  103)
Female nonclassic
CAH (n  31)
Hydrocortisone only
n (%) 24 (39%) 21 (20%) 5 (16%)
Median dose (range) (mg/d) 25 (10–60) 20 (10–32.5) 20 (10–25)
Administration (od/bd/tds) (n  51) 13/61/26%
Reverse circadian administration (n  51) 11%
Prednisolone only
n (%) 18 (29%) 50 (49%) 17 (55%)
Median dose (range) (mg/d) 7.5 (2.5–10) 6 (2.5–10) 5 (1–7.5)
Administration (od/bd/tds) (n  88) 24/75/1%
Reverse circadian administration (n  88) 60%
Dexamethasone only
n (%) 15 (24%) 17 (17%) 5 (16%)
Median dose (range) (mg/d) 0.5 (0.25–0.75) 0.375 (0.25–0.75) 0.25 (0.25–0.5)
Administration (od/bd/tds) (n  37) 78/22/0%
Reverse circadian administration (n  37) 44%
Combination of glucocorticoid preparationsa 4 (6%) 14 (14%) 2 (6%)
No glucocorticoids 1 (1%) 2 (6%)
Reverse circadian glucocorticoid administration 21 (34%) 51 (50%) 11 (35%)
Fludrocortisone
n (%) 51 (82%) 74 (72%) 3 (10%)
Median dose (range) (g/d) 125 (10–500) 150 (50–500) 50 (50–250)
a Overall, 20 of 199 patients received combined glucocorticoid treatment: hydrocortisone plus prednisolone (n  11), hydrocortisone plus
dexamethasone (n  4), prednisolone plus dexamethasone (n  4), hydrocortisone plus prednisolone plus dexamethasone (n  1). od, Once daily;
bd, twice daily; tds, three times daily.
FIG. 2. Serum levels of the androgen precursor androstenedione (A, C)
and the glucocorticoid precursor 17OHP (B, D) in male and female CAH
patients sampled in the morning after intake of the usual glucocorticoid
morning dose. The shaded areas represent recommended target range
(2). Note the logarithmic scale used for representing the serum hormone
concentrations.
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found in 27 and 30%, respectively, of female classic and
in 15 and 28% of female nonclassic CAH patients. In
males, androstenedione levels were suppressed (3.0
nmol/liter) in 29%and elevated in 35%of patients. There
was a significant correlation between 17OHP and andro-
stenedione measurements (r  0.621; P  0.001).
Serum 17OHP was much more variable than the andro-
gens and outside the previously recommended target range
(12–36 nmol/liter) (2) in the majority of patients. Forty-five
percent of female classic and41%of female nonclassicCAH
patients had 17OHP levels lower than 12 nmol/liter, and 43
and 35%, respectively, had 17OHP levels higher than 36
nmol/liter.Serum17OHPlevels showedsimilarvariability in
male CAHpatients, with 37%having levels under 12 nmol/
liter and 52%more than 36 nmol/liter.
Clinical characteristics and anthropometric data
(Table 2)
In comparison with age- and sex-matched HSE data,
CAHpatientswere significantly shorter, on average 14 cm
in men and 8 cm in women. Compared to population-
based controls, female patients had a greater waist cir-
cumference butmale patients did not differ from controls.
Both men and women with CAH had higher BMI than
HSE participants. Women with classic CAHwere shorter
and had higher BMI than women with nonclassic CAH.
Overall, 41% of CAH patients had a BMI in the obese
range (30.0 kg/m2), and 37% were overweight (25.0
and30.0 kg/m2). After adjusting for age distribution to
allow comparison with participants of 16–64 yr of age in
the HSE 2006, prevalence of obesity was 37.1% in men
with classic CAH (compared with 23.3% for men in HSE
2006) and 52.2 and 34.9%, respectively, in women with
classic and nonclassic CAH (compared with 26.5% for
women in HSE 2006).
The presence of stretch marks was common in both
sexes but more prevalent in women (62%) than in men
(38%). In females, 73% showed no or only mild signs of
hirsutism, 22% had moderate hirsutism, and in 5% hir-
sutism was graded severe.
Systolic blood pressure was slightly but significantly
lower in men with CAH than in population-based HSE
controls. Systolic blood pressure in women did not differ
from HSE data, but women with classic CAH had signif-
icantly higher diastolic blood pressure than age- and sex-
matched HSE controls.
Biochemical markers of metabolic risk
Total fasting cholesterol levels were higher than 5mmol/
liter in 46% of patients (male classic 36%, female classic
48%, female nonclassic 59%), and low-density lipoprotein
cholesterol was higher than 3mmol/liter in 39% of patients
(male classic 35%, female classic 37%, female nonclassic
60%).Decreased high-density lipoprotein cholesterol (1.0
and1.2 mmol/liter in men and women, respectively) was
found in 14%ofmale classic, 8%of female classic, and 7%
of female nonclassic patients.
Fasting plasma glucose was increased above 5.6 mmol/
liter in 8% of the patients (male classic 6%, female classic
7%, female nonclassic 13%). Insulin resistance as defined
TABLE 2. Age-weighted comparison of anthropometric and blood pressure data for the 21-hydroxylase deficiency
United Kingdom CaHASE cohort patients (n  199) with the normal United Kingdom population based on HSE data
Variable CAH HSE P, CAH vs. HSE P, CAH subgroup comparison
Height (cm)
Male classic (n  61) 162 176 0.0001
Female classic (n  103) 152 162 0.0001 0.0001a
Female nonclassic (n  31) 157 162 0.0001 0.003b
BMI (kg/m2)
Male classic (n  61) 27.2 27.2 1.0
Female classic (n  103) 32.9 26.7 0.0001 0.064a
Female nonclassic (n  31) 29.4 26.7 0.0064 0.24b
Waist circumference (cm)
Male classic (n  57) 96.7 94.4 0.24
Female classic (n  99) 99.5 85.9 0.0001 0.94a
Female nonclassic (n  31) 92.6 85.9 0.0043 0.36b
Sitting systolic blood pressure (mm Hg)
Male classic (n  61) 126 130 0.04
Female classic (n  102) 124 124 1.0 0.21a
Female nonclassic (n  30) 123 124 0.73 0.57b
Sitting diastolic blood pressure (mm Hg)
Male classic (n  61) 77.5 75.4 0.16
Female classic (n  102) 77.9 73.7 0.0002 0.96a
Female nonclassic (n  30) 74.4 73.7 0.54 0.48b
a Classic male vs. classic female CAH patients.
b Classic female vs. nonclassic female CAH patients.
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by homeostasismodel assessment of insulin resistance val-
ues below 2.5 was found in 29% of all patients (male
classic 36%, female classic 28%, female nonclassic 24%).
Bone mineral density
BMD data were available for 77 participants. Mean
SD lumbar and femoral BMD z-scores were0.34 1.47
and 0.25  1.01, respectively. The respective preva-
lences of osteopenia (BMD T-score1.0 to2.5) and
osteoporosis (BMDT-score2.5) were 39.2 and 6.8%
at the lumbar spine (L1–L4) and 28.8 and 1.4% at the
femoral neck.
Female fertility
At birth, 17 of the 138 females with CAH with con-
firmed 46,XX karyotype had been assigned male gender;
15 underwent gender reassignment, whereas two perma-
nently live as men. Sixty-nine percent of women (92 of
134) had undergone genital reconstruction surgery; 43%
underwent more than one operation, and 23% had sur-
gery in adulthood. In the majority (62%), a combination
of clitoral and vaginal surgery had been performed, and
isolated clitoral and vaginal procedures had been under-
taken in 24 and 14%, respectively.
Menarche occurred spontaneously in 80% of female
patients at a median age of 13 (range 9–25) years. At the
time of the study, 80 of 101 premenopausal women were
not taking oral contraceptives; 45%of them had irregular
menses (24% oligomenorrhea and 21% amenorrhea).
Overall, 35% of women had sought pregnancy (classic,
25%; nonclassic, 68%). Twenty-eight of 47 patients re-
ported 46 live births, including six conceived after fertility
treatment. The success rate of CAHwomen seeking preg-
nancy was 54% in the classic and 67% in the nonclassic
forms of CAH.
Male fertility
Twenty-four of 65 men (37%) had sought fertility and
16 of 24 (67%) had been successful, reporting 25 live
births, including two conceived after fertility treatment.
Testicular adrenal rest tumors (TARTs) were found in 11
of 16 patients (69%) investigated with ultrasound; only
four were palpable at clinical examination. An additional
four men had previously undergone unilateral orchidec-
tomy, with histopathology reporting benign Leydig cell
tumor, Leydig cell hyperplasia, and Leydig cell nodular
hyperplasia. Regarding fertility in the patients found to
have TARTs, seven never tried, one tried for 3 yr without
success, one is trying and still under treatment, and two
patients tried with success, achieving one and two live
births, respectively.
Quality of life analysis
Subjective health status was significantly impaired
across all eight SF-36 domains in the three CAH sub-
groups, with most prominent differences to age- and sex-
matched controls for the domains general health, vitality,
and role limitations due to emotional problems (Table 3
and Fig. 3A). TheHADS questionnaire revealed increased
anxiety scores for all three CAH subgroups and increased
depression scores in patients with classic CAH (Table 4
and Fig. 3B).
The IIEF-5 questionnaire was completed by 85% of
male CAH patients. Results revealed erectile dysfunction
in 41%(severe 10%,moderate 5%,mild tomoderate 9%,
and mild 17%). Only 70% of female patients returned a
completed McCoy sexuality questionnaire, and respond-
ers reported a high incidence of lack of vaginal lubrication
andpainduring intercourse (Table 5).Ofnote, this didnot
differ between female classic and nonclassic and whether
women had genital surgery or not. There was a slight but
significantly more pronounced lack of genital lubrication
in women without previous genital surgery (P  0.026)
(Table 5).
In their responses to the CAHwellbeing questionnaire,
only22and24%of femaleandmalepatients, respectively,
indicated that they were concerned about the impact of
CAHon their long-termhealth. Interestingly, only 35%of
both male and female patients reported concern about
their height. By contrast, 61 and 46% of female and male
patients, respectively, were concerned about their weight.
Only 26 and 18% of male and female patients, respec-
tively,wereworriedabout their fertilitypotential,whereas
46% of women and 38% of men were unhappy about
their sex life.
Discussion
This study establishes that the objective and subjective
health status in adultCAHpatients in theUnitedKingdom
is poor. This was observed for both sexes and in patients
with classic and nonclassic CAH alike. Females with clas-
sic CAH were the most affected. All patients, but in par-
ticular women with classic CAH, suffered from a high
prevalence of obesity (52.2% compared with 26.5% in
womenof 16–64 yr of age participating in theHSE2006),
hypercholesterolemia, insulin resistance, osteopenia, and
osteoporosis, and women with classic CAH also had in-
creased diastolic blood pressure when compared with
HSE participants. Glucocorticoid overtreatment is a
possible contributor to the observed adverse metabolic
profile, with women with classic CAH most frequently
receiving long-acting synthetic glucocorticoids, com-
bined treatment with several glucocorticoid prepara-
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tions, and reverse circadian glucocorticoid administra-
tion. The notion of excess glucocorticoid treatment in this
cohort was further supported by the frequent observation
of suppressed androgens, striae, and a greater reduction in
lumbar over femoral BMD, a common finding in glu-
cocorticoid-induced osteoporosis (23). Participants were
receiving a variety of different glucocorticoids, with dif-
ferent doses and frequencies and treatment prescribed in a
reverse circadian pattern to some participants (see Table
1). As a consequence, the study has limited power to
detect differences in outcomes between different treat-
ment groups, and a larger study is required to obtain this
important information.
A number of previous studies in small CAH cohorts of
young age have reported reduced BMD (24–26). A single-
center study in 55 adult womenwith classic CAH showed
a high incidence of osteopenia and osteoporosis (27) and
FIG. 3. Subjective health in status in CAH according to SF-36 (A) and
HADS (B) questionnaires and shown for male classic (n  65), female
classic (n  103), and female nonclassic (n  31) CAH patients with
box plots representing median and interquartile ranges; whiskers
represent the 5th and 95th percentiles. A z-score of 0 represents the
median of the normal reference population; the lower the SF-36 z-
scores and the higher the HADS z-scores, the worse is self-perceived
wellbeing and mood. SF-36 dimensions: PF, physical functioning; RP,
role limitations due to physical problems; BP, bodily pain; GH, general
health; VT, vitality; SF, social functioning; RE, role limitations due to
emotional problems; MH, mental health.
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also described increased fat mass and increased insulin
levels inpatientsover30yr (13).Thesepreliminary reports
are corroborated by our findings, although it should be
recognized that only a proportion of our patients had
BMD measurement at the discretion of the investigator,
and therefore, there may be a bias to find an increased
incidence of osteoporosis.
The frequent use of long-acting synthetic glucocorti-
coids and reverse circadian glucocorticoid administration
with the highest dose at bedtime, as observed in our co-
hort, contrasts with current pediatric practice where the
consensus suggests the use of the endogenous hormone
hydrocortisone (10). The benefit of reverse circadian glu-
cocorticoid administration has never been established,
and a recent study reported improved overnight control of
androgen excess in CAH by using a hydrocortisone for-
mulation capable of delayed and sustained release (8),
which may represent an option for improved glucocorti-
coid replacement (7).Despite glucocorticoidover-replace-
ment, the control of androgen excess in our cohort was
generally poor with the majority of patients having either
elevated or suppressed androgens. 17OHP levels were
even more variable, and half of our patients had levels
higher than 36 nmol/liter after the intake of their last glu-
cocorticoid dose [median time from last intake to blood
samplingwas 3.75 (interquartile range 2.25–12.5) hours].
This suggests that the currently recommended17OHPtar-
get range, 12–36 nmol/liter before morning dose (2),
strongly favors over-replacement and generally questions
the suitability of 17OHPasamonitoring tool inCAHwith
current therapy regimens.
In contrast to the suggestion of glucocorticoid over-
treatment, many of our patients appeared insufficiently
treated with mineralocorticoids, as indicated by raised
plasma renin in more than half of all patients and even in
one third of the patients receiving mineralocorticoid re-
placement. Aldosterone levels during the neonatal period
and childhood differ substantially from those during
adulthood (2,3).Therefore, reassessmentof volumestatus
and mineralocorticoid replacement requirements during
early adulthood is an important management step that
should not be overlooked (4, 5, 9).
Quality of life in our patients was significantly com-
promised, to a similar if not greater extent than previously
observed in adrenal insufficiency (28). Of note, our dis-
ease-specific questionnaire revealed that the significantly
reduced final height had a lesser self-perceived impact on
the adult patients than obesity or compromised sex life.
Similar to some smaller previous studies (29–32), we
found a low fertility rate in the overall cohort but a greater
fertility rate in those wanting to be fertile. Reasons will
vary but may include the consequences of genital sur-
gery (30) and the increased incidence of homosexual
orientation (11, 33). In our female patients, pain during
intercourse was a major perceived problem, supporting
previous findings in smaller cohorts (30, 34).
Over the last decade, it has become increasingly clear
that TARTs, i.e. nodular hyperplasia arising from cells
that have many characteristics of adrenocortical cells and
migrated with the testis during fetal development (35),
represent a significant problem in male CAH patients be-
cause they can severely compromise fertility (12, 36–39).
This is supported by the findings in our study that iden-
tified TARTs in themajority of male patients studiedwith
ultrasound, albeit that only a small number were investi-
gated. TARTs usually indicate poor disease control and
often are reversible after adjustment of glucocorticoid
treatment. It is of concern that four of our patients under-
went gonadectomy on the assumption of a seminoma,
with histology revealing TARTs, clearly indicating the
need for increased awareness of all clinicians involved in
the management of male CAH patients.
A major finding of our study was the low capture rate,
despite extensive recruitment by major United Kingdom
endocrine centers. Even when accounting for the recruit-
ment rate of 54% and overlooking the much higher num-
ber of to-be-expected nonclassic CAHpatients, we are left
with the fact that less than 10% of the expected adult
United Kingdom CAH patients are under endocrine spe-
cialist care. Where are the other patients? It is likely that
most patients born more than 60 yr ago are now deceased
because they were born before the availability of life-sav-
ing glucocorticoid treatment. Also, some of the younger
patients may not have survived, with 60% of our patients
presenting in the neonatal period being diagnosed only
after life-threatening adrenal crisis, consequent to the lack
of neonatal CAH screening in the United Kingdom. This
will affect in particular male patients who do not present
with ambiguous genitalia and thus fail to trigger early
diagnosis, which may contribute to the lower capture of
male patients in our study. For the majority of the missing
younger patients, we assume that many will either receive
no medical attention or are under the care of the family
physician or gynecologist.We should also be cautious that
wemay have a selection bias in that healthier patientsmay
not seek medical care.
In conclusion, this study demonstrates that health out-
comes in adults with CAH are generally poor in the CAH
patients receiving care at specialist centers studiedand that
currently only a small minority of patients in the United
Kingdom receive specialist care. Achieving improved care
by raising awareness of all physicians and enhancing tran-
sitionof carebetweenpediatric andadult endocrinologists
canbe expected to improveoutcomes; highernumberswill
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also translate into increased expertise of the involved spe-
cialists. We recommend that all adult patients with CAH
should be offered care in endocrine centers with appro-
priate expertise, involving a multidisciplinary team, in-
cluding endocrinologists, gynecologists, geneticists, psy-
chologists, urologists, and specialist nurses. We would
also stress the importance of transitional care between
pediatric and adult endocrinologists. The prevalent use of
long-acting synthetic glucocorticoids and in particular re-
verse circadian glucocorticoid administration in adults
with CAH is not supported by sufficient evidence, and
improving options for glucocorticoid treatment in CAH is
an important item on the research agenda.
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